Caitlyn Sams

Caitlyn Sams

Auto-generated profile, based on publicly available information

Caitlyn Sams

Cornell University 1 Department of Biomedical and Translational Sciences, College of Veterinary Medicine Ithaca, New York

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Although immune checkpoint blockade (ICB) therapy has generated dramatic responses in certain cancer types, breast tumors are largely unresponsive. Epithelial–mesenchymal plasticity (EMP) leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance of breast tumors to immunotherapies. Importantly, targeting CD73 completely sensitizes quasi-mesenchymal (qM) breast tumors to anti-CTLA4 ICB therapy. However, the mechanism(s) of sensitization remained unknown. We demonstrate that targeting CD73 in qM breast tumors sensitizes them to anti-CTLA4 ICB therapy in a CD4+ T cell–dependent manner. Moreover, EMP results in elevated expression of cancer cell–intrinsic CD73 in human triple-negative breast cancers. Given the ability of qM cancer cells to metastasize and resist multiple therapies, these findings can instruct the formation of translational strategies for the treatment of human breast cancers. These findings also bring to the forefront the attractive possibility of utilizing the phenotypic plasticity of cancer cells along with CD73 and CD4+ T cells as a predictive criterion for immunotherapy responsiveness. Significance: EMP enables metastasis and drives resistance to multiple treatment regimens. Our work underscores the possibility of utilizing CD4+ T cells, CD73, and cancer plasticity as predictive criteria for responsiveness to immunotherapy.

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Supplementary Figure S1. Targeting CD73 sensitizes quasi-mesenchymal tumors to anti-CTLA4 immune checkpoint blockade therapy

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
CD4+ T cells sensitize qM tumors lacking CD73 and MHC-I to anti-CTLA4 ICB. A, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. B, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. C and D, Representative immunofluorescence images of primary tumor sections obtained from (B) stained for CD4 (red), CD8 (white), and DAPI (blue) at 63× magnification. D, Bar graph represents quantification of CD4+ T cells in each high-power field (HPF) at 63× magnification for the indicated treatment groups. 3–5 fields of view from the tumor interior were obtained for each tumor. Data represent three independent experiments, with n = 3–5 mice in each group. E, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Data represent two independent experiments in which n = 3–9 for each group. F, Schema and tumor kinetics for CD73 and B2M DKO tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. G, Schema and tumor kinetics for CD73 and B2M DKO tumor-bearing mice treated with the indicated antibodies. Responders were rechallenged with the same cell line as indicated with or without treatment with anti-CD4. Data represent three independent experiments in which n = 3–7 for each group. A, B, and E–G, Data represent the SEM, two-way ANOVA, **, P < 0.01; ****, P < 0.0001. D, Data represent the SEM, two-tailed unpaired t test, **, P < 0.01. Scale bars are 100 μm.

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Supplementary Figure S2. Activation and exhaustion markers on CD8+ T-cell subsets present in responders and non-responders.

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Supplementary Figure S7. EMP regulates CD73 expression on human breast cancer cell lines

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Supplementary Figure S6. sgCD73 cells lacking MHC-I respond to anti-CTLA4 immune checkpoint blockade therapy in a CD4+ T-cell dependent manner.